Jun 13
2025
NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment
NeuroEM Therapeutics, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer’s disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc.
The Series A round supports continued progress toward commercialization of NeuroEM’s Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer’s and other neurodegenerative diseases.
“BlueLake’s support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer’s dementia and other neurodegenerative diseases,” says Chuck Papageorgiou, CEO of NeuroEM Therapeutics. “It fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer’s disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.”
The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors.
He brings more than 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo’s Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson.
“NeuroEM’s pioneering, non-invasive approach to treating and preventing Alzheimer’s represents exactly the kind of patented, deep tech innovation we champion at BlueLake—transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer’s holds tremendous promise in tackling a disease that has eluded effective solutions for decades,” said Rutledge. “We’re proud to support the advancement of this groundbreaking technology, and I’m personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.”
Adds Papageorgiou, “Jamie’s background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.”